Abstract. The nuclear lamina proteins, prelamin A, lamin B, and a 70-kD lamina-associated protein, are posttranslationally modified by a metabolite derived from mevalonate. This modification can be inhibited by treatment with (3-R,S)-3-fluoromevalonate, demonstrating that it is isoprenoid in nature. We have examined the association between isoprenoid metabolism and processing of the lamin A precursor in human and hamster cells. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate. Moreover, inhibition of prelamin A processing by mevinolin treatment is rapidly reversed by the addition of exogenous mevalonate. Processing of prelamin A is, therefore, dependent on isoprenoid metabolism. Analysis of the conversion of prelamin A to lamin A by two independent methods, immunoprecipitation and two-dimensional nonequilibrium pH gel electrophoresis, demonstrates that a precursor-product relationship exists between prelamin A and lamin A. Analysis of R,S-[5-3H(N)]mevalonate-labeled cells shows that the rate of turnover of the isoprenoid group from prelamin A is comparable to the rate of conversion of prelamin A to lamin A. These results~ suggest that during the proteolytic maturation of prelamin A, the isoprenylated moiety is lost. A significant difference between prelamin A processing, and that of p21 ra~ and the B-type lamins that undergo isoprenylationdependent proteolytic maturation, is that the mature form of lamin A is no longer isoprenylated.
lamin B, and a 70-kD lamina-associated protein, are posttranslationally modified by a metabolite derived from mevalonate. This modification can be inhibited by treatment with (3-R,S)-3-fluoromevalonate, demonstrating that it is isoprenoid in nature. We have examined the association between isoprenoid metabolism and processing of the lamin A precursor in human and hamster cells. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate. Moreover, inhibition of prelamin A processing by mevinolin treatment is rapidly reversed by the addition of exogenous mevalonate. Processing of prelamin A is, therefore, dependent on isoprenoid metabolism. Analysis of the conversion of prelamin A to lamin A by two independent methods, immunoprecipitation and two-dimensional nonequilibrium pH gel electrophoresis, demonstrates that a precursor-product relationship exists between prelamin A and lamin A.
Analysis of R,S-[5-3H(N)]mevalonate-labeled cells
shows that the rate of turnover of the isoprenoid group from prelamin A is comparable to the rate of conversion of prelamin A to lamin A. These results~ suggest that during the proteolytic maturation of prelamin A, the isoprenylated moiety is lost. A significant difference between prelamin A processing, and that of p21 ra~ and the B-type lamins that undergo isoprenylationdependent proteolytic maturation, is that the mature form of lamin A is no longer isoprenylated.
T HREE major polypeptides termed lamins A, B, and C (14, 17) comprise the nuclear lamina (1, 11, 16, 27, 28) of most mammalian somatic cells. Individual lamins are substrates for posttranslational modifications that include cell cycle-dependent phosphorylation (7, 15, 37, 42, 52) , methyl-esterification (9) , and covalent modification with a mevalonate-derived product (4, 6, 34, 47, 49, 50, 58) . The transient depolymerization of lamins, an event that is associated with the hyperphosphorylation of lamins (7, 14, 15, 37, 42) during mitosis, has been suggested to play a key regulatory role in the concomitant dissociation and reformation of the nuclear envelope. Membrane association appears to be an important function of the mevalonate-derived modifications to lamins in light of the apparent nuclear membrane localization of mammalian lamin B (7, 15, 18, 31) , chicken lamin B2 (55) , and the lamin A precursor polypeptide (22) , all of which are modified by isoprenoids. The isoprenoid substituent of lamin B(lla), p21 ra~ (8, 46) , and yeast polypeptide pheromones (3, 23, 25, 39, 45) has been identified as farnesyl.
Gerace et al. (17) have shown that in CHO cells, prelamin A becomes NP-40 insoluble within 5 min of synthesis, and that it is in this lamina-associated environment that processing to mature lamin A occurs. We have previously reported (4) that this 74-kD precursor form of lamin A is posttranslationally modified by a metabolic product derived from R-[2-~4C]mevalonate. Site-specific point mutation and deletion analyses have established that the carboxy-terminal -cysteinealiphatic-aliphatic-methionine (-C-A-A-M) ~ motif, acting in concert with other signal sequences, is required for efficient targeting of human prelamin A (22) and Xenopus lamins L~ and A (29) to the nuclear membrane. In mammalian (4, 17, 30, 42, 56) and avian (33, 55) cells, prelamin A to !amin A maturation is associated with a 2-kD decrease in molecular mass. We have demonstrated (4) that, after this maturation event, lamin A no longer contains the R-[2-~4C] mevalonatederived moiety.
In this report, we examine the processing of the 74-kD prelamin A precursor polypeptide in human (HeLa) and hamster (CHO-K1) cells. The requirement for mevalonate, and hence, isoprenoids, for the conversion of prelamin A to lamin A is demonstrated both in cultured cells treated with mevinolin as well as by mevalonate starvation of mev-1, a CHO-KI mevalonate auxotroph. The results presented in this report are consistent with the existence of an isoprenylation-dependent pathway for the formation of mature lamin A, and support our earlier proposal (4) that isoprenylation is a required step in the processing of prelamin A and other isoprenylated proteins. A CHO-KI derivative, met-18b-2, was a gift from Dr. J. Faust (Tufts University, Boston, MA). All cell culture reagents were from Gibeo Laboratories (Grand Island, NY). Fungizone (Amphotericin B) was obtained from E. R. Squibb (Princeton, N J). All other chemicals were purchased from Sigma Chemical Co.
Materials and Methods

Materials
Cell Culture and Radioisotopic Labeling
The cell lines used were CHO-K1 (26); mev-l, a CHO-Ki 3-hydroxy-3-methylglutaryl CoA synthase mutant (48, 5 l); met-18b-2, a CHO cell line that displays elevated mevalonate uptake and metabolism 02), and HeLa, a human adenocarcinoma cell line (24) . Cells were grown in Ham's F12 medium (20) , supplemented with FCS (5 % lvol/vol] for CHO cell lines and 10% [vol/vol] for HeLa), 100 U/ml penicillin, 100 #g/ml streptomycin, and 1 #g/ml Fungizone (medium I). Mev-1 cells were grown in medium I supplemented with 60 #g/ml mevalonate (medium II). Met-18b-2 cells were grown in medium I supplemented as described (12) with 8 #g/ml mevinolin and 37 #g/ml mevalonate (medium III).
For labeling with R,S-[5-3H(N)]mevalonate or R-[214C]mevalonate, cells were plated in the appropriate medium at one-half maximum density, and allowed to attach overnight. Before addition of mevalonate labeling medium, the cells were washed with PBS (130 mM NaCI, 2 mM KCI, 8 mM Na2HPO4, 2 mM KH2PO4, pH 7.2). Mevalonate labeling medium consisted of F12, penicillin, streptomycin, Fungizone, and 5% (vol/vol) dialyzed (against PBS) FCS (medium IV), and was supplemented with radiolabeled mevalonate (either 2-10 #Ci/ml of R-[2-14C]mevalonic acid lactone or 10 t~Ci/ml R,S-[5-3H(N)]mevalonolactone) with the appropriate concentrations of mevinolin (details are given in the figure legends). Mev-l cells are auxotrophic for mevalonate, and do not require mevinolin treatment to block endogenous mevalonate synthesis.
[35S]Methionine labeling medium (medium V) consisted of F12 containing one-half the normal methionine concentration, penicillin, streptomycin, Fungizone, 5% (vol/vol) dialyzed FCS, and 100 #Ci/ml [3SS]methionine.
Electrophoresis and Western Blotting
SDS-PAGE, two-dimensional nonequilibrium pH gel electrophoresis (2D-NEPHGE), and fluorography were performed as previously described (4) . E!ectrophoretic transfer of proteins to nitrocellulose membranes was performed at 4°C for 12-14 h at 30 V (100 mA) using a Hoefer TE Series Transphor Electrophoresis Unit (Hoefer Scientific Products, San Francisco, CA) in the Tris-glycine-methanol buffer system of Towbin (54) containing 0.1% (wt/vol) SDS.
lmmunoblot Analysis of Proteins Immobilized on Nitrocellulose
After electrophoretic transfer of proteins from the two-dimensional nonequilibrium pH gradient electrophoresis (2D-NEPHGE) gel, the nitrocellulose membrane was rinsed in TBS (20 mM Tris-HCi, pH 7.5, 500 mM NaCI) and blocked overnight at 4"C in TBS blocking buffer (TBS, 0.5% [vol/vol] Tween-20 and 5 % [wt/voll BSA [RIA gradeD. The nitnx~ilulose membrane was then rinsed in TBS and placed in 5 ml of TBS blocking buffer containing a 1:1,000 dilution of LSI anti-lamin (A + C) antiserum (35) . After incubation for 6-12 h at 4°C with the primary antibody, the nitrocellulose membrane was washed twice in TBS with 0,05% Tween-20 for 10 rain at 4"C. The nitrocellulose membrane was then reacted with goat anti-human IgGalkaline pbosphatase conjugate at a l:l,000 dilution in TBS, 5% (wffvol) BSA for 1-2 b at 25°C. The nitrocellulose membrane was then rinsed three times for 5 rain in TBS. Color development of the alkaline phosphataseconjugated second antibody was performed according to the manufacturer's directions.
Filter Binding Assay for p~S]methionine and
R-[2-UC]mevalonate-labeled Proteins
A small fraction of the R-[2-14Clmevalonate is incorporated into isopentenyl tRNA (47, 50) , which must be hydrolyzed (100 #g/ml RNase A, 37°C, 30 min) before precipitation of proteins with TCA. Carder protein and lipids were added in the form of FCS (20 #l/assay). The samples were then adjusted to 10% (wt/vol) 'IV_A, and incubated on ice for at least 60 rain. Samples were transferred to GF/A glass microfiber filters (Whatman Inc., Clifton, NJ) and washed sequentially with three 5-mi volumes each of acetone, followed by chloroform:methanol (2/1), and 95% ethanol. The filters were dried and radioactivity determined.
Results
Inhibition of Mevalonate Biosynthesis Prevents the Conversion of Prelamin A to Lamin A
We have demonstrated (4) The silver-stained 2D-NEPHGE gel of a nuclear lamina intermediate filament fraction from similarly treated HeLa cells contains a similar complement of proteins ( Fig. 1 B) . 
Immunological Identification of Prelamin A and Lamin A in Nuclear Lamina Intermediate Filament Preparations
We have shown (4) that prelamin A migrates on 2D-NEPHGE gels with an identical set of pH isovariants and at a slightly higher molecular mass than lamin A, is precipitated with antilamin (A + C) antiserum, and exhibits peptide mapping homology with lamin A. We now present immunological evidence identifying the 74-kD R- cumulates under conditions of mevalonate starvation. Also present in these ceils is mature lamin A that was synthesized and processed during the preliminary 7 h growth in the absence of mevinolin. In contrast, the autoradiogram from cells not treated with mevinolin ( Fig. 2 B) illustrates that cells grown in the absence of mevinolin process prelamin A normally.
Positive identification of these polypeptides as prelamin A and lamin A was made by immunoblot analysis using an antilamin (A+C) serum. Both prelamin A and mature lamin A, (Fig. 2 C) are present in mevinolin-treated cells. In contrast, only lamin A is detectable in the immunoblots from untreated cells (D). Immunoblot analyses of nuclear lamina intermediate filament preparations from a number of similarly treated cell types yield identical results (Beck, L. A., C. H. Campbell, J. Logel, and M. Sinensky, submitted for publication). Both the 74 kD R-[2-~4C]mevalonate-labeled polypeptide and the 72 kD nonisoprenylated lamin A are recognized by an antilamin (A + C) antibody, consistent with their identification as lamin A and its precursor polypeptide, prelamin A. Only in mevinolin-treated cells, in the absence of any exogenously added mevalonate, does prelamin A accumulate to a detectable level (Fig. 2 A) . Even the addition of trace amounts of mevalonate, present only as R-[2-'4C]mevalonate, results in a sufficient intracellular concentration of mevalonate to allow biosynthesis of isoprenoids, posttranslational modification, and processing ofprelamin A ( Fig. 1 A and B) . The R-[2-~4C]mevalonate-labeled 74-kD pre-lamin A fiuorographic signal (Fig. 1, C and D) is produced by those molecules of prelamin A that have been modified by the mevalonate-derived product but have not yet been processed. (41) of pyrophosphomevalonate decarboxylase. This enzyme catalyzes the reaction leading directly to isopentenyl pyrophosphate, the immediate precursor to all isoprenoids. Treatment ofCHO met-18b-2 cells with (3-R,S)-3-fluoromevalonate inhibits the posttranslational modification of proteins with a metabolic product derived from R-[2-~4C]mevalonate in a dose-dependent manner (Fig. 3 A, solid circles) . Inhibition by (3-R,S)-3-fluoromevalonate is specific for the isoprenylated proteins, since it produces only a slight effect on the incorporation of [35S]methionine into total cellular protein ( Fig.   3 A, open circles) . Consistent with the postulated isoprenoid nature of this type of modification to the lamina proteins, (3-R,S)-3-fiuoromevalonate blocks the R-[2-~*C]mevalonatederived labeling of proteins of nuclear lamina intermediate filament preparations (Fig. 3 B, solid circles) with little effect on the net synthesis of these proteins as measured by psS]methionine labeling (Fig. 3 B, open circles) . These results are consistent with the premise that the mevalonate-derived modification to prelamin A, as well as to other mevalonate-labeled proteins, is isopentenyl pyrophosphate, or an isoprenoid moiety metabolically distal to isopentenyl pyrophosphate.
Verification of the Isoprenoid Nature of the Mevalonate-derived Modification
Inhibition of the Processing of Prelamin A to Lamin A Is Not Due to Nonspecific Mevinolin Effects
It was important to confirm that the block to prelamin A processing is a direct consequence of mevinolin depletion of isoprenoids, and is not due to nonspecific mevinolin effects. We compared the processing of prelamin A in mevinolintreated CHO-K1 and HeLa cells to the processing of prelamin A in a cell line auxotrophic for mevalonate (mev-l), grown under conditions of mevalonate starvation. These studies demonstrate (Fig. 4) that only mature lamin A is present in control CHO-K1 or HeLa cells grown in the absence of mevinolin (Fig. 4, lanes a and d) , or in Mev-1 cells supplemented with exogenous mevalonate (Fig. 4, lane g ). Accumulation of prelamin A can be manifested either by mevinolin treatment of CHO-K1 or HeLa cells (Fig. 4 , lanes b and e) with mevinolin, or by growth of Mev-1 in the absence of exogenous mevalonate (Fig. 4, lane h) . To test further that processing of prelamin A is mevalonate-dependent, cells were treated simultaneously with mevinolin and mevalonate. Under these growth conditions, cells contain only mature lamin A (Fig.  4, lanes c,f, and i ). These results demonstrate that (a) mevalonate starvation, whether the consequence of mevinolin treatment or auxotrophy, blocks the processing of prelamin A; and (b) the presence of mevalonate, even during mevinolin treatment, restores isoprenoid synthesis and allows processing of prelamin A to lamin A.
Kinetics of Prelamin A Processing: lmmunoprecipitation Analysis
We 
Kinetics of Prelamin A Processing: 2D-NEPHGE Analysis
As an independent method of examining the kinetics of prelamin A processing, we used a 2D-NEPHGE/fluorographic analysis of nuclear lamina intermediate filament preparations from HeLa cells labeled with [35S]methionine in the presence or absence of mevinolin. Consistent with the data obtained from the immunoprecipitation analysis of untreated HeLa cells (Fig. 5 A, lane a) , we found that all of the [35S]methionine labeled lamin A in nuclear lamina intermediate filament preparations from untreated cells is present as the mature 72-kD form (Fig. 6 A; note the absence of prelamin A). In mevinolin-treated cells, processing is blocked and the lamin A precursor polypeptide accumulates (Fig. 6 B) . The rate of conversion of [35S]methionine-labeled prelamin A to lamin A from parallel cultures, that had been transferred to unlabeled chase medium containing 1 mM exogenous mevalonate (Fig. 6 C-F) , was identical to the data presented in Fig. 5 A. By 120 min (Fig. 6 D) , after release from the mevinolin block, most of the prelamin A has been converted to lamin A. From 120 to 250 min after the addition of mevalonate (Fig. 6 D, E, and F), there is a steady decrease in prelamin A accompanied by a concomitant increase in lamin A. At 250 min (F), newly synthesized prelamin A is no longer detectable.
Quantitation of the Precursor Product Relationship between Prelarain A and Lamin A
Radioactive spots corresponding to prelamin A, lamin A, and 13 other well-separated and clearly distinguishable [35S]-methionine-labeled polypeptides were excised from a representative subset of 2D-NEPHGE gels obtained from this analysis and counted. The fractional change in the amount 
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Time of Mevalonate Chase (h) Figure 7 . Quantitation of the precursor product relationship between prelamin A and lamin A. A subset of the fluorograms obtained from the 2D-NEPHGE/fluorographic analysis of the prelamin A to lamin A processing (see Fig. 6 ) were used as templates to carefully excise the [3SS]methionine-labeled prelamin A, lamin A, and 13 other well-separated and clearly identifiable polypeptides. The gel slices were dissolved in 30% hydrogen peroxide at 65°C, and the radioactivity was contained in each polypeptide determined by liquid scintillation counting. The fractional ratio of the radioactivity contained in each polypeptide spot, relative to the tohal radioactivity contained in all 15 spots, was then determined. tent with the premise that the loss of the isoprenoid substituent is associated with the proteolytic processing mechanism during the conversion of prelamin A to lamin A.
Discussion
In earlier reports we have shown that prelamin A, lamin B, and a 70 kD lamina-associated polypeptide are posttranslationally modified with a metabolite derived from R-[2J4C] -mevalonate (4) . In this report we confirm the isoprenoid nature of this modification by demonstrating that (3-R,S)-3-fluoromevalonate inhibits the incorporation of R-[2-14C] -mevalonate into these proteins (Fig. 3) . We have identified the 74 kD isoprenylated protein as prelamin A on the basis of its subcellular distribution, migration on 2D-NEPHGE gels, and peptide maps (4). Furthermore, it is recognized on 2D-NEPHGE/immunoblots with antilamin (A + C) antibodies (Fig. 2) . Mevalonate starvation and subsequent depletion of isoprenoid pools can be effected by mevinolin treatment or through auxotrophy (Fig. 4) . The metabolic consequence of either treatment is inhibition of isoprenoiddependent proteolytic processing, rapidly followed by an accumulation of prelamin A. Subsequent addition of mevalonate abolishes isoprenoid starvation and allows in vivo conversion of prelamin A to lamin A (Figs. 5 and 6 ). The rate of this conversion (Fig. 7) is similar to the loss of the isoprenoid moiety from prelamin A (Fig. 8 B) .
of radioactivity contained in the prelamin A and lamin A polypeptide spots, relative to the totalradioactivity contained in all 15 spots, was then determined. The result of this examination (Fig. 7) demonstrates that (a) prelamin A accumulates as a consequence of a mevinolin-induced isoprenoid starvation; (b) prelamin A is converted to lamin A with a half-life of ~90-120 min after the removal of the mevinolin block; and (c) prelamin A and lamin A exhibit a precursor product relationship.
Kinetics of the Loss of the lsoprenoid Substituent from Prelamin A
We next compared the rate of loss of the isoprenoid moiety from prelamin A with the rate of conversion of prelamin A to lamin A. (Fig. 8 A) was then analyzed by densitometry. The results of this analysis are presented in Fig.  8 B. The loss of the isoprenoid substituent from prelamin A is relatively rapid, displaying a half-life, determined graphically, of '~100-120 min. In contrast, lamin B and the 70-kD lamina-associated protein are characterized by a very stable form of isoprenylation. This rate of loss of the isoprenylated substituent from prelamin A is comparable to the rate of conversion of prelamin A to lamin A, as determined from the immunoprecipitation and 2D-NEPHGE/fluorographic analyses presented in Figs. 5, 6, and 7. These results are consis-
The -C-A-A-X Carboxy Terminal Motif of Prelamin A Is Required for Its Maturation to Lamin A
Clarke et al. have catalogued a number of proteins that contain a -C-A-A-X carboxy terminal amino acid sequence (10) . They have suggested that this consensus amino acid sequence may provide a general recognition site for posttranslational modifications that include lipidation and carboxymethylation. This sequence is present in yeast peptidyl pheromones (3, 5, 38, 46) , yeast rasl and ras2 (43, 46) , and mammalian p21 r~ (8, 10, 19, 21, 46, 57) . Mammalian and avian lamins, characterized by a -C-A-A-M carboxy terminal motif (55) , can be considered a subfamily of this class of proteins. The similarity between the -C-A-A-X motif of ras proteins, yeast peptidyl pheromones, and the -C-A-A-M motif of lamins, in addition to their posttranslational isoprenylation, suggests that the functional role of this carboxy terminal sequence may be similar. Moreover, ms proteins, yeast peptidyl pheromones, and B-type lamins undergo proteolytic processing and membrane localization subsequent to isoprenylation. We propose, as has Holtz et al. (22) , that prelamin A is also a nuclear membrane protein and that nuclear membrane localization is required for its processing and assembly into the lamina. The isoprenylated form of prelamin A is hypothesized to be required for this membrane localization.
lsoprenylation Is Required for the Processing of Prelamin A to Lamin A
We have demonstrated that depletion of endogenous isoprenoid pools through mcvinolin treatment can block the processing of prelamin A. This occurs in HeLa and CHO-K1 cells (Figs. 1, 2 , and 4), as well as in a number of other human, hamster, and chicken cell lines (our unpublished data). Starvation of the mevalonate auxotroph Mev-1 (Fig. 4) verifies that the inhibition of prelamin A processing is a specific consequence of isoprenoid starvation and is not due to nonspecific mevinolin effects. Furthermore, the inhibition of processing is readily reversible. In mevinolin-treated cells, addition of exogenous mevalonate initiates protein isoprenylation, followed rapidly ( (55) . In addition, they have demonstrated that this processing pathway is mevalonate dependent. Similarly, a cysteine to methionine mutation in the -C-A-A-M motif of human prelamin A blocks nuclear envelope association and proteolytic processing (22) . These mutational studies on the presumed isoprenylation site of these proteins are also consistent with our proposal that isoprenylation is required for the processing of prelamin A.
Processing of Prelamin A Involves the Loss of the lsoprenylated Moiety
Analysis of mature lamin A by peptide mapping revealed that the entire carboxy terminal -C-A-A-M motif of prelamin A is cleaved during maturation, whereas in lamin B2 at most three amino acids are lost (55, 56) . We have clearly demonstrated ( Figs. 1 and 8 , and reference 4) that, lamin B retains its isoprenylation, whereas mature lamin A does not. Lamin C, which is missing the carboxy terminal 93 amino acids that are present in lamin A (13, 36) , is not isoprenylated ( Fig. 1 ; reference 4), further supporting the premise that the -C-A-A-M motif is the site of isoprenylation. Sequence analysis (56) of the carboxy-terminal 14-kD fragment of mature murine lamin A has revealed that mature lamin A lacks the carboxy terminal 18 amino acids predicted from the prelamin A cDNA sequence (13, 36) , thus providing direct evidence that mammalian prelamin A maturation occurs by carboxy terminal proteolysis. It is reasonable, therefore, to presume that the polypeptide removed from prelamin A during the endoproteolytic processing event contains the isoprenylated moiety.
In agreement with this assumption, is our demonstration that the rate of loss of isoprenylation from prelamin A (Fig. 8) is similar to the rate of conversion of prelamin A to lamin A (Figs. 5-7 ). These lines of evidence, combined with our in vivo demonstration of mevalonate dependency for the conversion of prelamin A to lamin A, are not consistent with the earlier suggestion (32) that the 72-kD lamin A polypeptide arises artifactually. The data presented here support the hypothesis that the loss of isoprenylation from prelamin A during maturation is due to its localization (presumably the cysteine residue of the -C-A-A-M motif) at the carboxy terminus. Confirmation of this premise must await chemical identification of the derivatized amino acids and direct sequencing of the carboxy terminus of prelamin A.
Prelamin A Maturation: Similarity to Other Systems
The sequence of metabolic events implicated in the maturation of prelamin A is analogous to that described for yeast peptidyl pheromones and ras proteins. In Tremella mesenterica, the mating pheromone tremerogen A-10, is isoprenylated with a farnesyl substituent in a thioether linkage to the carboxy terminal cysteine residue of the -C-A-A-X motif (39, 40) . After isoprenylation, the 26-kD precursor polypeptide becomes membrane bound where it is processed to a 24-kD polypeptide and the 2-kD mature pheromone (39, 40) . In like manner, Saccharomyces cerevisiae a-mating factor is synthesized as a higher molecular mass precursor and, after isoprenylation of the -C-A-A-X cysteine residue with a farnesyl moiety, undergoes endoproteolytic as well as carboxy terminal processing (3, 46) . Other studies have shown that both carboxy terminal processing and membrane localization of p21 r'~ are dependent on isoprenylation (3, 10, 19, 21, 46, 57) .
Processing of Prelamin A: A Proposed Model
Our results, together with those presented by a number of other laboratories, enable us to propose the following model for the isoprenylation-dependent maturation of prelamin A. Prelamin A is transported rapidly into the nucleus after translation. We hypothesize that, in analogy to steps described above for the maturation of p21 r~s, yeast peptidyl pheromones, and chicken lamin B2, prelamin A is then isoprenylated, presumably at the cysteine of the carboxy terminal -C-A-A-M motif. This facilitates its association with the nuclear membrane, the site of the subsequent proteolytic removal of three C-terminal amino acid residues. This carboxypeptidase-type processing of prelamin A yields a prelamin A intermediate containing an isoprenylated carboxy terminal cysteine. The nature of the isoprenylation reaction is not yet understood, however, in preliminary studies we have found that nonisoprenylated prelamin A is transported into the nucleus. In the final stage of the maturation pathway, a membrane-bound endopeptidase cleaves an additional polypeptide from the carboxy terminus of prelamin A. The loss of this polypeptide, which presumably contains the isoprenoid substituent, accounts for the 2-kD molecular mass shift observed during maturation of prelamin A. Whether other posttranslational modifications are also involved in the altered mobility observed during processing of prelamin A is still not known.
Additional mammalian proteins that undergo an isoprenylation-dependent proteolytic maturation most likely exist since mevinolin treatment has been shown to alter the electrophoretic mobility of a number of cytosolic, isoprenylated proteins in murine erythroleukemic cells (44) . The variability in the fate of the isoprenylated moiety, and the proteins so modified, advances the possibility of different isoprenoid substituents, multiple prenyl-transferases, endopeptidases, and/or carboxy peptidases involved in this pathway for proteolytic maturation.
